Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase NA 19Phase 3 9Phase 1 3Phase 2/3 2Phase 1/2 2Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 161Neoplasms 95Prostatic Neoplasms 86Glioblastoma 76Multiple Myeloma 65Pancreatic Neoplasms 63Glioma 61Brain Neoplasms 56Lung Neoplasms 46Carcinoma, Hepatocellular 44Melanoma 43Head and Neck Neoplasms 43Recurrence 41Carcinoma, Non-Small-Cell Lung 41Leukemia, Myeloid, Acute 40Colorectal Neoplasms 38Squamous Cell Carcinoma of Head and Neck 35Ovarian Neoplasms 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 31Neoplasm Metastasis 29Lymphoma, Non-Hodgkin 29Lymphoma 28Carcinoma, Renal Cell 28Polycystic Ovary Syndrome 27Stomach Neoplasms 24Hematologic Neoplasms 23Lymphoma, B-Cell 22Sarcoma 21Endometrial Neoplasms 20Uterine Cervical Neoplasms 19

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × Pathologic Complete Response × Clear all
NCT03832569 2026-03-05

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Active not recruiting
17 enrolled

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon âš¡